Coral Calcium Hydrogen Reduces Skin Inflammation as Well as Steroids
- Authors
- Gaoxiang Huang, Dongmei Wei, Wei Zhao, Hao Xu, Yankang Wang, Xinyao Fu, Ye Yang, Rong Li, Xuzhen Wang, Kai Zhou, Jing Luan
- Journal
- Journal of Inflammation Research
- Year
- 2026
- DOI
- 10.2147/JIR.S571870
- Study Type
- Mouse
- Outcome
- Positive
- Peer Reviewed
- Yes
- Country
- China
- Health Condition
- Allergic Contact Dermatitis
- Body System
- Integumentary
TL;DR
Oral coral calcium–carried hydrogen reduced skin inflammation and immune activation in a mouse model of allergic contact dermatitis, with effects comparable to dexamethasone.
Key Finding
In mice with allergic contact dermatitis, coral calcium carried hydrogen reduced skin inflammation and immune markers comparably to dexamethasone, a standard steroid medication.
Summary
Researchers tested a new hydrogen-delivery product called coral calcium carried hydrogen (CCH) in mice with allergic contact dermatitis, a skin condition caused by an overactive immune response. CCH worked about as well as dexamethasone, a standard steroid treatment, at reducing skin inflammation, scratching, and swelling. The CCH appeared to work by reducing certain immune cells and inflammatory molecules in the blood.
Practical Takeaway
This is an early-stage animal study only, so results cannot be directly applied to humans yet. While the findings suggest CCH may have anti-inflammatory potential, human clinical trials would be needed to determine if it is safe or effective for treating skin conditions in people.
Abstract
IntroductionAllergic contact dermatitis (ACD) is a common T cell-mediated delayed hypersensitivity reaction characterized by chronic skin inflammation. Coral calcium carried hydrogen (CCH), a novel solid-phase hydrogen carrier, enables sustained hydrogen release and demonstrates superior stability compared to conventional hydrogen delivery methods. However, its therapeutic potential in ACD remains unexplored.MethodsACD was induced in female BALB/c mice (8-week-old) using 2,4-dinitrochlorobenzene (DNCB). Mice were divided into four groups: Control, DNCB model, CCH-treated (oral CCH), and dexamethasone (DEX)-treated (oral DEX). Disease severity was assessed through dermatitis scores, scratching frequency, spleen coefficient, and histopathological analysis. Serum cytokine levels and peripheral blood immune cell profiles were evaluated to elucidate the underlying mechanisms.ResultsCCH treatment significantly ameliorated ACD symptoms, comparable to DEX, as evidenced by reduced dermatitis scores, scratching behavior, and spleen enlargement. Histologically, CCH promoted ulcer healing and more effectively suppressed epidermal hyperplasia and skin inflammation than DEX. Mechanistically, CCH selectively reduced serum IgE and IL-17 levels while decreasing lymphocyte counts and proportions. In contrast, DEX primarily inhibited monocytes and neutrophils.ConclusionCCH exerts its therapeutic effects by modulating lymphocyte-mediated immune responses and suppressing pro-inflammatory cytokines, offering a promising therapeutic alternative with efficacy comparable to glucocorticoids.